{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:04:36Z","timestamp":1789473876302,"version":"build-2803163510"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eururo.2026.07.025","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:32:25Z","timestamp":1789471945000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Challenges of Using Circulating Tumour DNA: Insights from Advanced Prostate Cancer"],"prefix":"10.1016","author":[{"given":"Tarek","family":"Taha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ossian","family":"Longoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.07.025_b0005","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.euo.2025.04.016","article-title":"Efficacy of anti-PD-(L)1 immunotherapy in patients with DNA mismatch repair-deficient metastatic castration-resistant prostate cancer","volume":"8","author":"van Wilpe","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.07.025_b0010","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2026.01.015","article-title":"Advanced and metastatic prostate cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.07.025_b0015","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.07.025_b0020","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","article-title":"Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms","volume":"27","author":"Tukachinsky","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2026.07.025_b0025","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41580-025-00936-y","article-title":"Inflammageing and clonal haematopoiesis interplay and their impact on human disease","volume":"27","author":"Hajishengallis","year":"2026","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.eururo.2026.07.025_b0030","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","article-title":"Elucidating acquired PARP inhibitor resistance in advanced prostate cancer","volume":"42","author":"Seed","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2026.07.025_b0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat Rev Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382602302X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382602302X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:32:26Z","timestamp":1789471946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382602302X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":7,"alternative-id":["S030228382602302X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.07.025","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges of Using Circulating Tumour DNA: Insights from Advanced Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}